mercredi 15 novembre 2017

Onco Actu du 15 novembre 2017

2.6 Etiologie - Environnement

Monsanto, U.S. farm groups sue California over glyphosate warnings [Reuters]

5. Traitements

Science Surgery: ‘Is the one-size-fits-all treatment approach obsolete?’ [Cancer Research UK]

Alternate Driver of Treatment-Resistant Prostate Cancer Identified [NCI]

5.10 Traitements - Essais

Navigating the new Clinical Trial Regulation with DIA [Pharmafile]

5.12.1 Immunothérapies - partenariats

Seres teams with cancer heavyweights for microbiome-checkpoint inhibitor combination trial [FierceBiotech]

Biotech firms race to recruit good bugs in war on cancer [Reuters]

5.12.8 Immunothérapies - Economie

With $25M, Torque Aims for a More Targeted Cell Therapy for Cancer [Xconomy]

5.2.1 Pharma - Partenariats

In a Precision Step, Bayer Writes Loxo $400M Check for Two Cancer Drugs [Xconomy]

Loxo Sells Bayer Rights To Rare Cancer Drug For More Than $1 Billion [Forbes]

Loxo's Good Deed Goes Punished [Bloomberg]

Loxo signs lucrative cancer drug deal with Bayer, but shares fall [Reuters]

Loxo Oncology Announces Global Development and Commercialization Partnership with Bayer for Larotrectinib and LOXO-195 [Loxo]

5.2.3 Pharma - économie

San Diego’s stealthy Odonate surfaces with $173M IPO [EndPoints]

5.3 Traitements - FDA, EMA, NICE...

EMA to work with stakeholders to improve the product information for EU medicines [EMA]

5.3.4 Traitements - AMM (FDA, EMA)

Faslodex receives US FDA approval for the treatment of advanced breast cancer in combination with abemaciclib [AstraZeneca]

5.7.1 SABCS-communiqués

Novartis presents new data at SABCS across broad range of breast cancer patient populations, combination treatments and lines of therapy [Novartis]

6. Lutte contre les cancers

Three charts on: brain cancer in Australia [The Conversation]

UK Biobank Supercharges Medicine with Gene Data on 500,000 Brits [MIT Technology Review]